Nuvalent, Inc. (NUVL)

97.93 -0.07 (-0.07%) USD  |  NASDAQ  |  Mar 13, 16:00
97.95 +0.02 (+0.02%) After-Hours: 20:00
More

Nuvalent Revenue Estimates for Next Quarter

Revenue Estimates for Next Quarter Chart

View Revenue Estimates for Next Quarter for NUVL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue Estimates for Next Quarter Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Revenue Estimates for Next Quarter Range, Past 5 Years

View Revenue Estimates for Next Quarter Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue Estimates for Next Quarter Benchmarks

View Revenue Estimates for Next Quarter Benchmarks
Start Trial
Glaukos Corp. Upgrade
Edgewise Therapeutics, Inc. Upgrade
Cogent Biosciences, Inc. Upgrade
Neurocrine Biosciences, Inc. Upgrade
Vanda Pharmaceuticals, Inc. Upgrade

Revenue Estimates for Next Quarter Related Metrics

Revenue Estimates for Current Fiscal Year Upgrade
Revenue Estimates for Next Fiscal Year Upgrade
EPS Estimates for Current Quarter Upgrade
EPS Estimates for Next Quarter Upgrade
EPS Estimates for Current Fiscal Year Upgrade
EPS Estimates for Next Fiscal Year Upgrade